Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.
Sath Shukla sold 155,333 shares of SPRO on 5 February at $0.78 per share, worth a total of $121K. They now own 1,886,077 SPRO shares, or a 8% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
